Prevalence and management of treatment-resistant depression

Research output: Contribution to journalShort survey

235 Scopus citations

Abstract

Treatment-resistant depression (TRD) is a major public health problem in terms of its prevalence and in terms of individual suffering and cost to society. Best estimates indicate 12-month prevalence rates of ∼3% for Stage 1 TRD (failure to respond to 1 adequate trial of an antidepressant) and ∼2% for Stage 2 TRD (failure to respond to 2 adequate trials). The current article provides a brief review of the definitions, prevalence, and various treatment options for TRD, including switching, augmentation, and combination therapies and use of nonpharmacologic treatments. Given the public health importance of TRD, the relative absence of adequately powered, double-blind trials is striking.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalJournal of Clinical Psychiatry
Volume68
Issue numberSUPPL. 8
StatePublished - Aug 6 2007
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Prevalence and management of treatment-resistant depression'. Together they form a unique fingerprint.

  • Cite this